Comparison of Solifenacin and Oxybutynin in the Treatment of Overactive Bladder: An Observational Comparative Study
Introduction/ background: Overactive bladder (OAB) impairs quality of life, and antimuscarinic agents remain the mainstay of its drug treatment. Oxybutynin is non-selective and frequently causes anticholinergic adverse effects, whereas solifenacin is relatively M3-selective; local comparative data on their efficacy and tolerability are limited. Objective: To compare the efficacy and adverse effects of solifenacin and oxybutynin in patients with overactive bladder (OAB). Study Design and Setting: Prospective cohort study; Department of Physical Medicine and Rehabilitation, Armed Forces Institute of Rehabilitation Medicine (AFIRM), Rawalpindi, Pakistan, from July 2026 till September 2026 (ERC Case No. 01/2025). Methodology: After ethical approval, 170 patients aged 18–65 years with OAB diagnosed by International Continence Society criteria and symptoms for ≥3 months were enrolled by non-probability consecutive sampling. Patients were grouped according to the drug prescribed by the treating physician in routine care: Group A (n=85) received solifenacin 5 mg once daily and Group B (n=85) received immediate-release oxybutynin 5 mg three times daily, for 3 months. Daytime frequency, urgency, nocturia and urge incontinence episodes (recorded in a voiding diary kept for three consecutive days before each assessment) and the OAB symptom severity score (0–12) were assessed at baseline and at 3 months; adverse effects were recorded at each follow-up visit (weeks 2, 4, 8 and 12). Data were analysed in SPSS v29.0. Change from baseline was compared between groups by independent-samples t-test, and adverse effects by chi-square or Fisher’s exact test; p≤0.05 was considered significant. Results: The groups were comparable at baseline in age (42.3±11.4 vs 43.6±12.0 years), gender, BMI and duration of symptoms (all p>0.05). At 3 months, reductions from baseline were significantly greater with solifenacin than with oxybutynin for daytime frequency (33.0% vs 24.8%), urgency (54.9% vs 35.7%), nocturia (58.4% vs 37.9%), urge incontinence (66.8% vs 43.6%) and total OAB score (56.5% vs 38.7%) (all p≤0.002). Adverse effects were less frequent with solifenacin (24.7% vs 72.9%, p<0.001), including dry mouth (14.1% vs 44.7%), constipation (9.4% vs 34.1%), blurred vision (5.9% vs 25.9%), dizziness (4.7% vs 21.2%) and self-reported cognitive disturbance (2.4% vs 17.6%). Fewer patients discontinued treatment because of adverse effects with solifenacin (3.5% vs 16.5%, p=0.005). Conclusion: In this single-centre cohort, solifenacin was associated with greater improvement in OAB symptoms and fewer adverse effects than immediate-release oxybutynin. Solifenacin may be considered in preference to immediate-release oxybutynin when an antimuscarinic is prescribed; randomised trials are needed to confirm these findings.
Authors
- Aqsa Anwar
- Danish Ali Mir
- Waleed Latif
- Farooq Azam Rathore
- Muhammad Ammar Khan
- Muhammad Zeeshan Nawaz
Publication Details
- Journal
- Annals of PIMS-Shaheed Zulfiqar Ali Bhutto Medical University
- Published
- 2026-11-20
- DOI
- https://doi.org/10.48036/hbvf7f59
- Primary Topic
- Urinary Bladder and Prostate Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00